Literature DB >> 8175390

Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy.

H Hatanaka1, Y Nakagawa.   

Abstract

PURPOSE: The present report is a review of long-term survivors in the patients with malignant brain tumors treated by boron neutron capture therapy. METHODS AND MATERIAL: One-hundred twenty patients with 119 intracranial tumors and one extracranial nerve-related tumor were treated by the current standard technique of boron-neutron capture therapy (BNCT) as of December 1992, using 10B-sodium-mercaptoundecahydrododecaborate.
RESULTS: Out of 87 patients operated on before May 1987, 18 lived or have lived longer than 5 years. Nine of these 18 lived or have lived longer than 10 years out of 53 patients operated on before May 1982. Among more-than-10-year survivors, only two died at 17 and 12 years. All of the other are still alive. The two died of delayed radiation damage because BNCT was applied to glioblastomas which recurred after their conventional radiotherapy. They lacked evidence of tumors when they died. Out of these nine more-than-10-year survivors, three had been previously treated by conventional external radiotherapy and they developed radiation damage which brought all patients ultimately to an incapacitated condition. Two of the three died. All the other 6 who were free from previous radiation history are active in their jobs and have no evidence of tumors.
CONCLUSION: It can be suggested that BNCT is a radiotherapy that can produce "cure" of both malignant and benign brain tumors while preserving a good quality of life if conducted without conventional radiotherapy.

Entities:  

Mesh:

Year:  1994        PMID: 8175390     DOI: 10.1016/0360-3016(94)90479-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  37 in total

Review 1.  Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors.

Authors:  N Gupta; R A Gahbauer; T E Blue; B Albertson
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

Review 2.  Targeted drug delivery for boron neutron capture therapy.

Authors:  S C Mehta; D R Lu
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

3.  Selective boron delivery by intra-arterial injection of BSH-WOW emulsion in hepatic cancer model for neutron capture therapy.

Authors:  Hironobu Yanagie; Novriana Dewi; Syushi Higashi; Ichiro Ikushima; Koji Seguchi; Ryoji Mizumachi; Yuji Murata; Yasuyuki Morishita; Atsuko Shinohara; Shoji Mikado; Nakahiro Yasuda; Mitsuteru Fujihara; Yuriko Sakurai; Kikue Mouri; Masashi Yanagawa; Tomoya Iizuka; Minoru Suzuki; Yoshinori Sakurai; Shin-Ichiro Masunaga; Hiroki Tanaka; Takehisa Matsukawa; Kazuhito Yokoyama; Takashi Fujino; Koichi Ogura; Yasumasa Nonaka; Hirotaka Sugiyama; Tetsuya Kajiyama; Sho Yui; Ryohei Nishimura; Koji Ono; Sinichi Takamoto; Jun Nakajima; Minoru Ono; Masazumi Eriguchi; Kenichiro Hasumi; Hiroyuki Takahashi
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

4.  Postoperative treatment of glioblastoma with BNCT at the petten irradiation facility (EORTC protocol 11,961).

Authors:  K Hideghéty; W Sauerwein; K Haselsberger; F Grochulla; H Fankhauser; R Moss; R Huiskamp; D Gabel; M de Vries
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

5.  Intracavitary moderator balloon combined with (252)Cf brachytherapy and boron neutron capture therapy, improving dosimetry in brain tumour and infiltrations.

Authors:  S F Brandão; T P R Campos
Journal:  Br J Radiol       Date:  2015-04-30       Impact factor: 3.039

6.  Determination of the subcellular distribution of mercaptoundecahydro-closo-dodecaborate (BSH) in human glioblastoma multiforme by electron microscopy.

Authors:  Michael Neumann; Ulrike Kunz; Heiner Lehmann; Detlef Gabel
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

7.  Subcellular biodistribution of sodium borocaptate (BSH: Na2B12H11SH) in a rat glioma model in boron neutron capture therapy.

Authors:  Teruyoshi Kageji; Shinji Nagahiro; Birte Otersen; Detlef Gabel; Manekazu Nakaichi; Yoshinobu Nakagawa
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

Review 8.  Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation.

Authors:  Rolf F Barth; Weilian Yang; Jeffrey A Coderre
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

9.  Histopathological findings in autopsied glioblastoma patients treated by mixed neutron beam BNCT.

Authors:  Teruyoshi Kageji; Shinji Nagahiro; Shinichi Uyama; Yoshifumi Mizobuchi; Hiroyuki Toi; Muneo Nakamura; Yoshinobu Nakagawa
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

10.  Tissue uptake of BSH in patients with glioblastoma in the EORTC 11961 phase I BNCT trial.

Authors:  Katalin Hideghéty; Wolfgang Sauerwein; Andrea Wittig; Claudia Götz; Philippe Paquis; Frank Grochulla; Klaus Haselsberger; John Wolbers; Ray Moss; Rene Huiskamp; Heinz Fankhauser; Martin de Vries; Detlef Gabel
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.